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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized
by severe cytokine storm syndrome following inflammation. SARS-CoV-2 directly
interacts with angiotensin-converting enzyme 2 (ACE-2) receptors in the human body.
Complementary therapies that impact on expression of IgE and IgG antibodies,
including administration of bee venom (BV), have efficacy in the management of
arthritis, and Parkinson’s disease. A recent epidemiological study in China showed
that local beekeepers have a level of immunity against SARS-CoV-2 with and
without previous exposure to virus. BV anti-inflammatory properties are associated
with melittin and phospholipase A2 (PLA2), both of which show activity against
enveloped and non-enveloped viruses, including H1N1 and HIV, with activity mediated
through antagonist activity against interleukin-6 (IL-6), IL-8, interferon-γ (IFN-γ), and
tumor necrosis factor-α (TNF-α). Melittin is associated with the underexpression of
proinflammatory cytokines, including nuclear factor-kappa B (NF-κB), extracellular
signal-regulated kinases (ERK1/2), and protein kinase Akt. BV therapy also involves
group III secretory phospholipase A2 in the management of respiratory and neurological
diseases. BV activation of the cellular and humoral immune systems should be explored
for the application of complementary medicine for the management of SARS-CoV-2
infections. BV “vaccination” is used to immunize against cytomegalovirus and can
suppress metastases through the PLA2 and phosphatidylinositol-(3,4)-bisphosphate
pathways. That BV shows efficacy for HIV and H1NI offers opportunity as a candidate
for complementary therapy for protection against SARS-CoV-2.
Keywords: bee venom, complementary medicine and alternative medicine, SARS-CoV-2 (2019-nCoV),
pharmokinetics of bee poison, COVID-19 and complementary medicine, bee venom in clinical trials
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INTRODUCTION
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) is the causal agent of coronavirus disease 2019 (COVID-
19), a respiratory infection that emerged in Wuhan province
of China in late 2019 (1, 2), becoming a global pandemic in
2020. By April 1, 2020, global mortality rates were reaching
5% (3). Within weeks, global mortality rates increased to
6.7% (5% for the African region, 4.4% for the Americas,
5% in the Eastern Mediterranean region, 4.4% for Southeast
Asia, 8.9% for the European region, 4.4% in the Western
Pacific region) (4). The public health challenges imposed by
COVID-19 are immense, including management of the high
number of asymptomatic cases (5). The disease has exacerbated
existing socioeconomic disparities, especially in vulnerable
communities in developing countries, including Africa, that have
disproportionately been affected by the consequences of extreme
preventative measures (6).
Severe SARS-CoV-2 infections are characterized by cytokine
storm syndrome, hyperinflammation, and multiorgan failure (2,
7). Host cells are infected through the angiotensin-converting
enzyme 2 (ACE-2) receptor (8, 9), associated with both
innate and acquired immunity (10). ACE2 is considered to
enhance viral replication and potentiate host cell invasion
(10) and is a major component of the renin-angiotensin-
aldosterone system (RAAS), interacting with enzymes of the
CVS to cascade cardiovascular disease (11, 12). ACE2 may
be the reason SARS-CoV-2 patients require pharmacological
thrombosis prophylaxis (13, 14); the pathogenesis of SARS-CoV-
2 involves viral binding to epithelial cells and local propagation
with minimal innate immune response (15). The second stage of
infection exhibits increased viral propagation, an active immune
response, viral spread to the lower respiratory system, and may
include cardiovascular and digestive systems (16). The third
stage involves hypoxia, infiltration of the entire respiratory
system, and finally acute respiratory distress syndrome (ARDS),
which is potentially fatal (15). SARS-CoV-2 is associated
with coagulopathies, thrombotic events (17) and lymphocyte
exhaustion (18).
At present, there is no globally accepted alternative
medical treatment protocol against SARS-CoV-2, although
administration of polyclonal antibodies shows some promise
(19). The efficacy of chloroquine and its derivatives continue
to be explored for prevention of COVID-19 (20, 21) as well
as Famotidine, an antiulcer drug, administered at high dosage
(10× normal) for 14 days for control of SARS-CoV-2 infection
(7). Remdesivir, which has previously been used to manage the
Middle East Respiratory Syndrome-Cronavirus (MERS-CoV)
has been explored as a candidate drug against SARS-CoV-2
(22–24). Combinations of Lopinavir/ritonavir, commonly used
to prevent HIV/AIDS are also under investigation for efficacy
against SARS-CoV-2 (25, 26). Neutrophil extracellular traps
(NETs), common in snakes, insects, arachnids and myriapods
have also been considered for SARS-CoV-2 (27, 28). Bee venoms
(BVs) can act as ACE2 inhibitors or angiotensin-receptor
blockers (ARBs), although studies on BVs and SARS-CoV-2 are
sparse. Snake venom is known to act through phospholipase A2
(PLA2) to produce arachidonic acid, which induces hypotension
(29). In humans, hymenoptera venom lowered key parameters
in the RAAS (30). A combination of BV and propolis has been
associated with hypotension in laboratory animals through a
reduction in serum angiotensin levels (31), demonstrating a
close relationship between BV and the ACE2 pathway.
BEE VENOM THERAPY
Bee venom (BV) therapy dates back to the era of Hippocrates,
where it was deployed to alleviate joint pain and arthritis (32).
In contemporary medicine, BV is deployed for treatment of
multiple sclerosis (33), arthritis and Parkinson’s disease (34).
Activity is based on anaphylactic reaction benefits on metabolism
and on organelles, especially those of the respiratory system (35).
Allergens may offer benefits against COVID-19 (36, 37); BV can
induce elevation of specific IgE and IgG antibodies (38) and leads
to production of IgE antibodies, which can respond to a variety of
antigens (39) (Table 1). Although IgE are responsible for allergic
outbursts, they also offer host protective roles over a wide range
of allergens (39). BV can act as an adjuvant when combined with
Toll-like receptor (TLR) ligands (40) and modulate the immune
system, enhance the differentiation of foxP3-expressing cells and
increase circulating regulatory T cells (41, 42). BV triggers an
increase in CD25, CD4+ T cells and foxP3 mRNA, resulting
in a shift in the BV-specific IgG4/IgE ratio (43). BV regulates
the immune response and phsiopathological changes (44) and
supports clinical observations in Apitherapy, where beekeepers
were shown to mount immunity against COVID-19 in Wuhan
province, PR China (45).
The bvPLA2 can trigger mast cell maturation (46), is
important in cell signaling and for production of key lipids and
may act as a receptor ligand (47). PLA2 can inhibit the flow
of inflammatory cells to targets (48). BVs may lead to lasting
induced tolerance to related allergens (49), as a function of
reducing IgG4 and activating IL-10, modulating the immune
system and inducing deviation from TH2 to TH1(50–52).
Melittin (APi M 1) can be used to develop mimotopes (49).
APi M 10 (icarapin), a BV component, activates effector cells
of honey bee venom allergic patients (53). Since IgE possesses
an epitope for APi M 10, this may offer opportunity for
adjuvant development. BV antigens can be used as adjuvants
in the treatment of pain (54) and the action of melittin on
cell membrane pore formation (54, 55), leading to apoptosis
serves to strengthen adjuvant properties. BV also has antiviral
properties (56). BV can desensitize mast cells and basophils (57)
and suppress innate lymphoid cells. BV materials can inhibit
proteinsynthesis, induce angiogenesis (58) and activate caspase-
3-8-9 (59) (Table 1).
CONDITIONS THAT ALLOW BEE VENOM
USE DESPITE ITS TOXICITY
Bee venom is cytotoxic at high doses, however, non-cytotoxic
concentrations of BV range from 1 to 3µg/ml, show significant
therapeutic potential (60). Low doses, controlled concentrations,
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TABLE 1 | Bee venom enzymes and peptides and their functions in mammalian systems.
References Component Compound Properties/mode of action % BV Properties / mode of action for mammalian analog
Dams and Briers (130)
Wehbe et al. (103)
Enzyme Hyaluronidases Breakdown of hyaluronic acid to increase tissue permeability,
accelerated distribution of toxins “spreading factor”
Increases bioavailability of drugs, used in therapy of extravasations,
management of complications associated with aesthetic injection of
hyaluronic acid-based fillers
1–3 Ubiquitous in somatic tissues
Six forms in humans (HYAL1-4, HYAL-P1, and PH-20)
PH-20 has highest activity, highest in testicles and involved in
fertilization process
Breaks down tissue hyaluronic acid and chondroitin sulfate
increasing tissue permeability e.g., of sperm during adhesion and
penetration to cumulus oophorus
Boens et al. (131)
Szulc and Bauer,
(131, 132)
Enzyme Acid phosphatases Hydrolyzing monophosphate esters to release products associated
with pain and inflammation,
Potent releaser of histamine in human basophils, thus relevant in
allergic process
1 In prostate, erythrocytes, macrophages, platelets, bones, spleen,
lungs, testes
Hydrolyzes phosphate
Enzyme dysregulation is associated with pathophysiological
conditions e.g., prostatic acid phosphatase (cancer of prostate);
tartrate-resistant acid phosphatase (abnormal bone resorption in
osteoporosis)
Released by platelets during clotting. Binding to α2-macroglobulin
leads to a reduction in its activity
Murakami et al. (133)
Stahelin (134)
Enzyme Phospholipase A2
(PLA2)
Most lethal enzyme in BV
Formation of melittin-PLA2 complex referred to as the bee hemolytic
factor that cleaves cellular membrane phospholipids and cellular lysis
Potent allergen
Trypanocidal, antibacterial, neuronal protection, anti-tumor properties.
Hepato-protective in acetaminophen-induced liver damage
10–12 Ubiquitous in many cells and tissues (pancreas, spleen, liver,
intestines, spleen, lung, heart, testis, brain, macrophages,
inflamed tissues, and inflammatory cells).
Involved in inflammation: generation of precursors of eicosanoids
(prostaglandins, leukotrienes), platelet-activating, factor; cell
activation via a specific receptor; digestion and metabolism of
dietary phospholipids; host defense and signal transduction,
exocytosis, antimicrobial activity, anticoagulation, ischemia, brain
development
Overproduction of lipid mediators associated with PLA2 activity
can cause inflammation and tissue disorders
PLA2 is expressed in alveolar macrophages during inflammation to
clear lung exudates, and by cytokine induction and
airway dysfunction
Connolly et al. (135)
Lima and
Brochetto-Braga (91)
Enzyme Phosphomonesterase Acid phosphatase with similar properties 1 Found in accessory reproductive organs (prostate and seminal
vesicles) and in other parts of the genital tract (testis, vas deferens,
epididymis)
Hydrolyses choline-O-phosphate
Involved in calcium metabolism during blood clotting
Alkaline phosphomonesterases involved in wound healing
Activity increased in kidney from dioxydin accumulation.
Brás et al. (136) Enzyme α-glucosidase Associated with honey production by bees 0.6 Four human forms in digestive system [salivary and pancreatic
α-amylases (endohydrolase); α-maltotriose (oligoglucans);
α-maltase-glucoamylase and α-sucrose-isomaltase
(exohydrolases)]
Essential for digestion of starch to glucose
Facilitates glucose absorption especially by enterocytes
Involved in metabolic disorders such as type 2 diabetes and
obesity due to hyperglycemia
Application for anti-diabetic agents
(Continued)
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TABLE 1 | Continued
References Component Compound Properties/mode of action % BV Properties / mode of action for mammalian analog
Holtsberg et al. (137)
Karamitros and Konrad
(137, 138)
Enzyme Lysophospholipase Increases PLA2 activity.
PLA2 degrades phospholipids into lisophospholipids that are cleaved
by the lysophospholipases into glycerophosphocoline and anionic
fatty acids
1 Found in eosinophils, pancreas, brain, liver, lactating mammary
glands, and most (if not all) cells
Breaks down phosphatidylcholine to glycerophosphate-choline to
release choline.
Hydrolyses lysophospholipids and attenuates lysophosphatidic
acid-mediated signal transduction in nervous tissues
Pancreatic form is involved in digestion
Eosinophilic form is involved in immunologic function
Those with an N-terminal L-Asparaginase domain have role in
amino acid metabolism useful in medical and therapeutic
applications e.g., antileukemic protein drug
Soliman et al. (57, 139)
Pucca et al., (57, 139)
Peptide Melittin Most toxic component
Attacks lipid membranes causing cell lysis, haemolysis, cytotoxicity,
and biodegradation
Forms melittin-PLA2 complex that causes cellular injury
Induces mild allergic but severe pain reactions
In cancer therapy due to its cytotoxic activity on cancer cells
Control of excessive immune responses
Anti-inflammatory, antimicrobial, antiviral, fungicidal, and
anti-cancer properties
40–60
Pucca et al. (57, 140)
Issa et al., (57, 140)
Peptide Apamin Inhibits Ca2+-dependent K+ channels (blocks potassium
permeabilities) facilitating the crossing of the blood brain barrier
Causes neurotoxic effects such as intense local pain, hyperactivity,
seizures, tonic-clonic convulsions, jerks, spasms
Potential treatment for neurological disabilities such as learning deficit
disorder, Parkinson’s disease by activating of inhibitory muscarinic
receptors of motor nerve terminals
1–3 Tissues with acceptor receptors for apamin in lower mammals: rat
brain, rat neuroblastoma, rat and guinea pig liver, guinea pig colon,
synaptosomes, rat myotubes
Moreno and Giralt (85). Peptide Mast cell degranulating
peptide
Inflammatory and anti-inflammatory properties:
inflammation/allergy: at low concentration it induces massive release
of histamine, serotonin and vasoactive amines from mast cells
-anti-inflammatory/ anti-allergic: in high quantity it inhibits mast cell
degranulation by inhibiting histamine
Can cause hyperexcitability in mammalian neurons (convulsant)
Potential to induce allergy and inflammation by inducing secretion of
mast cells, basophils, and leukocytes is of value in designing
therapeutic compounds
2–3
Seo et al. (77)
Cherniack and Govorus
(76)
Gu et al. (78)
Peptide Adolapin Inhibits cyclooxygenase activity and blocks prostaglandin synthetase
system leading to antipyretic, anti-inflammatory and
anti-nociceptive/analgesic cascades
Inhibits lipoxygenase from human platelets
Elevates the c-GMP level in rat spleen and brain and inhibits
phospholipase A2, c-AMP in rats’ spleen
Utilized in bee venom acupuncture to successfully manage
musculoskeletal diseases (lumbar disc disease, osteoarthritis of the
knee, rheumatoid arthritis, adhesive capsulitis, and lateral epicondylitis)
1
(Continued)
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. and diluted BVs trigger a range of anti-inflammatory responses
(61, 62), and have been deployed for management of diabetes,
rheumatoid arthritis (RA), heart disease, obesity, asthma, skin
diseases, and central nervous system-associated diseases, such
as Alzheimer’s disease, Parkinson’s disease, and sclerosis (61–
64). At low doses, BV can suppress inflammatory cytokines
such as interleukin-6 (IL-6), IL-8, interferon-γ (IFN-γ), and
tumor necrosis factor-α (TNF-α). A decrease in the signaling
pathways responsible for the activation of inflammatory
cytokines, such as nuclear factor-kappa B (NF-κB), extracellular
signal-regulated kinases (ERK1/2) and protein kinase Akt, and
porphyromonas gingivalis lipopolysaccharide (PgLPS)-treated
human keratinocytes has been associated with treatments
involving BV (65).
BV has been used as an anti-inflammatory agent by
combining compounds in BV, i.e., secretory phospholipase A2,
with phosphatidylinositol-(3,4)-bisphosphate or cells, mainly
dendritic cells (DCs), or combining BV with DCs (66).
Conjugation of hormone receptors and gene therapy transporters
to BV peptides as a useful novel targeted therapy to positively
modulate immune responses has been applied in anticancer and
anti-inflammatory therapy (67).
BV immune reactions are toxic at high doses but when
controlled or diluted (controlled concentrations) these immune
reactions can serve as immune modulators. Controlled allergic
immunity can be advantageous for host defense against antigens
and pathogens including RNA viruses. BV can stimulate type 2
immune responses, type 2 immunity is initiated by T-cell (T-
helper type 2) and immunoglobulin (Ig) antibodies (IgE and
IgG1) and the action of the innate immune system, such as
the epithelium and white blood cells and serves as a barrier
defenses to eliminate antigens (68). BV group III sPLA2 shows
in vitro and in vivo effects on the immune system. Modulated
immune reactions from BV can alleviate immunological illnesses
such as rheumatoid arthritis, inflammatory illnesses, asthma, and
Parkinson’s disease (69). The innate immune system induces a
defensive immune response against BV antigens through pattern-
recognition receptors (PRRs), including Toll-like receptors found
on pathogen-associated molecular patterns (PAMPs) (70). BV
in therapeutic disease, is anti-inflammatory (44) decreasing
numbers of infiltrated inflammatory cells, and the expression of
tumor necrosis factor (TNF)-α, interleukin (IL)-1β, inhibition
Toll-like receptor (TLR)2 and CD14. BVs also suppress the
binding potential of nuclear factor-κB (NF-κB) and activator
protein (AP)-1 (71). Human IL-1 receptor (anakinra) also shows
anti-inflammatory activity (72), however information linking this
receptor and Bee venom remain sparse.
Bee venom phospholipase 2 (bvPLA2) is the main allergen
in BV and stimulates the innate immune system by binding
to pattern-recognition receptors (PRRs), e.g., Toll-like receptors
that recognize pathogen-associated molecular patterns (PAMPs),
triggering a type 2 immune response. bvPLA2 induces T-helper
cell-type reactions and group 2 innate lymphoid cells (ILC2s)
facilitated through the enzyme-aided cleavage of membrane
phospholipids and secretion of IL-33. bvPLA2 also induces the
production of IgE shown to be protective in mice from future
allergic/immunologic reactions [in the case of a lethal dose
Frontiers in Public Health | www.frontiersin.org 5 December 2020 | Volume 8 | Article 594458
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FIGURE 1 | Cellular and microbial targets relevant to bee venom components and targets for future research. Bee venom acts through dendritic cells to stimulate the
immune system through which it activates cellular immunity. Its antioxidant activity is associated with a reduction in reactive oxygen species (ROS) and elevation in
antioxidant enzymes (e.g., GSH and PON1), which leads to protection against cell death.
of BV (70)]. PLA2 plays a vital role in host defense in Th2
differentiation, ILC2 activation, immunoglobulin production,
membrane remodeling, and anti-inflammatory reactions (44, 70).
BV shows positive immune-modulating roles; reducing
the progression of tumors and activating the immune
system by combining bvPLA2 with phosphatidylinositol-
(3,4)-bisphosphate or cells, mainly dendritic cells (DC) (66).
DCs prepared with BV in vivo have both anticancer and antiviral
properties. DCs combined with antigens from a tumor or virus
produce major histocompatibility complex (MHC) class I and II
peptides epitopes to CD8 and CD4 T lymphocytes (Figure 1).
PLA2 (bvPLA2-H34Q) is membrane-binding and in vivo
combines antigens with the human DC cell membrane,
causing stimulation of CD8T cells and antiviral and antitumor
vaccines (DC vaccine) can be obtained from BV using DCs.
These cell-based antiviral/antitumor vaccines are used during
immunization against viruses including cytomegalovirus and for
tumor suppression (73, 74). BV is a known adjuvant-potentiated
antimicrobial and antitumor vaccine. Melittin, bvPLA2 and
phosphatidylinositol-(3,4)-bisphosphate are effective adjuvants
for anti-leishmania, anti-tumor and anti-cytomegalovirus
vaccines (73–75). Conjugation of BV peptides with hormone
receptors and gene therapy offer to positively modulate
immune responses applied offer targeted anticancer and
anti-inflammatory therapies (67).
BV can be used as an analgesic at controlled dose
concentrations; inhibiting cyclooxygenase activity and blocking
the prostaglandin synthetase system, leading to antipyretic, anti-
inflammatory, and anti-nociceptive/analgesic cascades (76–78).
In diluted form BV can induce anti-nociceptive effects via the
α-adrenergic receptor (activation of the spinal α-adrenergic
receptor) (61, 62). Conjugation of BV peptides to protein
receptors such as hormones and genes transporting the peptides
provides an innovative BV controlled anti-inflammatory, anti-
nociceptive, and immune-modulatory therapy (67).
PHARMACODYNAMICS OF BEE VENOM
CONSTITUENTS
Bee venom (BV) contains enzymes [phospholipase
A2 (PLA2), phospholipase B, hyaluronidases, acid
Frontiers in Public Health | www.frontiersin.org 6 December 2020 | Volume 8 | Article 594458
Kasozi et al. Bee Venom for COVID-19
phosphatases, acid phosphomonesterases, α-D-glucosidases,
and lysophospholipases]; peptides [lytic peptide melittin,
apamin, mastocyte (mast cell) degranulating peptide, secapine,
pamine, minimine, procamine A, B, protease inhibitor,
tertiapine, cardiopep, and adolapin] (30–33); and amino
acids include g-aminobutyric acid and a-amino acids. Non-
peptide components include amines (dopamine, histamine,
norepinephrine, neurotransmitters), carbohydrates (glucose,
fructose), pheromones (iso-pentyl acetate; n-butyl acetate;
iso-pentanol; n-hexyl acetate; n-octyl acetate; 2-nonanol; n-decyl
acetate; benzyl acetate; benzyl alcohol; and (2)-11-eicosen-1-ol)
(79, 80) (Table 1).
BV has been shown to have anti-inflammatory,
antinociceptive, antioxidant, and anti-apoptotic properties
and has been shown to alter gene expression and fibrosis
(81–84). Side effects include proinflammation [higher doses of
PLA2, mast cell degranulating peptides, hemolytic compounds
(melittin)], allergic reactions to protease inhibitors and peptides,
anaphylactic responses and death (76).
Multiple protein allergens in bee venom are responsible for
the allergic response (85). Allergic reactions can take place in
the respiratory system, gastrointestinal system, cardiovascular
system, skin and stings and can result in severe anaphylactic
shock, sometimes leading to cerebral or myocardial ischemia
(86, 87). A non-immune-mediated mechanism of allergy to
BV involves the production of bradykinin (BK) mediators,
leading to anaphylaxis (88) from melittin activation of PLA2
(mimicking BKs).
BIOLOGICAL VARIABILITY OF BEE VENOM
COMPOSITION AMONG BEE VARIANTS
FOR BIOTOXIN ADMINISTRATION IN
COMPLEMENTARY MEDICINE
Bees and wasps belong to the insect order Hymenoptera
(89, 90). In bees, venom production is highest for queen
bees on emergence. Hymenoptera venom causes toxic or
allergic reactions mostly caused by biochemical compounds
associated with local inflammatory action (91, 92). Stings
defend the colony in all insects of the order Hymenoptera
(93, 94). Melittin is the most prominent compound responsible
for these allergic reactions (95, 96); although a combination
of mastocytes with IgE invokes activity of leucotrienes,
histamines and platelet activating factors during allergic
reactions (93, 94, 97).
Hymenoptera venoms contain dopamine, adrenaline,
hyaluronidase, noradrenaline, serotonin, histamine,
phospholipases A and B (85) but only BV contains mast
cell-degranulating peptide, melittin and apamin (57). Different
bee species bees; Apis mellifera mellifera and Apis mellifera
ligustica (in Europe) and Apis mellifera scutellate (in Africa) are
responsible for human envenoming (57). The median lethal
dose of BV ranges from 2.8 to 3.5 mg/kg body weight, and on
average, 140–150 µg of BV is injected in a stinging episode (57).
The chances of death from only a few bee stings is minimal in
non-allergic persons (98) and the severity of the envenomation
is duly influenced by the body weight, age and immune status of
the victim (99, 100). Sting number and any previous sensitization
to BV affect envenoming severity (99, 100).
BV is a clear, odorless, colorless watery liquid with a pH of 4.5–
5.5 with a bitter taste and in some cases an ornamental pungent
smell (101, 102). BV composition is affected by extraction
methods due to its volatility (101). Apis mellifera venom is
arguably the best characterized venom in Hymenoptera (103).
Venom from all Apis species is similar in composition and
quality. A. florea, a honey bee is smallest in its family, while A.
dorsata is the largest (101). Apis cerana venom is twice as tocic
as that of Apis mellifera (104). Differences in the composition of
venom gland and venom sac secretion and the concentration of
lipids, proteins, activity of acid phosphatase and hexokinase have
been observed in the venom glands of A. dorsata > A. cerana >
A. mellifera > A. florea. Lipid, protein, carbohydrate and alkaline
phosphatase compositions have been found to be in the order of
A. cerana > A. mellifera > A. florea. Glycogen was absent in both
the venom gland and venom sac of Apis species (101).
Variability in bee venom composition is related to species, age,
geographic localization and social condition (96). Young worker
bees have lower concentrations of melittin and histamine and
higher concentrations of apamin than older worker bees (57).
Queen bees have low concentrations of melittin and apamin
and high concentrations of histamine (57). APi M reaches its
peak when the bee is ∼28 days old and declines with age
(105). Levels of PLA2 reach a maximum at around day 10 of
hatching (101). African bees release small quantities of venom in
stinging episodes, with high concentrations of PLA2 and reduced
concentrations of melittin and hyaluronidase (57). Seasonal
variations in the composition of the BV have been reported
(106); for example, during winter, APi M production increases
but decreases during summer (107, 108).
CURRENT THERAPEUTIC ADVANCES OF
BEE VENOM
Antiviral and Antibacterial Properties
Melittin and PLA2 exhibit antimicrobial activities and have
been used as complementary antibacterial agents (103); inducing
pore formation and destruction of bacteria (109). APi M shows
antiviral properties against some enveloped viruses and non-
enveloped viruses in vitro (110). Protection has been observed in
mice following exposure to influenza A H1N1 virus but BV can
also interact directly the viral surface (110) (Figure 2).
Management of Cancer
BV has been explored in cancer (111, 112); melittin is
considered cytolytic but non-specific. Melittin can break down
the membrane lipid bilayer and exhibits toxicity when injected
intravenously (113). APi M has the ability to suppress tumor
growth in breast, liver, prostate, and lung cancer cells (111, 112).
In vitro and in vivo studies show that melittin can suppress
growth of cancerous cells by inhibiting NF-κB signaling and
activating caspase 3 and 9 pathways. Inhibition of hepatocellular
carcinoma cell motility was observed in vitro and in vivo by
suppression of Rac1-dependent pathways (114).
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FIGURE 2 | Antimicrobial and immunomodulatory actions of various bee venom components. BV inhibits bacterial, antifungal and viral growth while stimulating
dendritic cell activity through major anti-inflammatory cytokines. This offers a rationale for its use in complementary medicine to control the SARS-CoV-2 pandemic.
Anti-inflammatory Potential
Low doses of BV trigger a range of anti-inflammatory responses
that have been explored in diabetes, rheumatoid arthritis
(RA), heart diseases, obesity, asthma, skin diseases, and
central nervous system-associated diseases (Alzheimer’s
disease, Parkinson’s disease, and amyotrophic lateral sclerosis)
(63, 64). BV suppresses inflammatory cytokines, including
interleukin-6 (IL-6), IL-8, interferon-γ (IFN-γ), and tumor
necrosis factor-α (TNF-α). A decrease in the signaling
pathways responsible for the activation of inflammatory
cytokines, nuclear factor-kappa B (NF-κB), extracellular
signal-regulated kinases (ERK1/2) and protein kinase Akt, and
Porphyromonas gingivalis lipopolysaccharide (PgLPS)-treated
human keratinocytes are associated with melittin treatment
(65) (Figure 2).
HOST RESPONSES TO BEE VENOM
BV therapy can alleviate immune-related illnesses. Group III
secretory phospholipase A2 from BV (BV group III sPLA2)
shows in vitro and in vivo activity on the immune system
and has been used to manage asthma, Parkinson’s disease, and
drug-induced organ inflammation (69). BV immune reactions
can be dangerous when highly elevated, but when controlled,
allergic immunity can be advantageous in host defense to
stimulate type 2 immune responses. Type 2 immunity is mainly
based on barrier defenses, and these responses are initiated
by T helper type 2 (TH2) cells, immunoglobulins E and G1
(IgE and IgG1) antibodies, and other components of the innate
immune system (epithelial barriers, innate lymphoid cells-ILCs,
eosinophils, mast cells, basophils, and activated macrophages)
(68). The innate immune system senses components of venom,
inducing a defensive immune response against antigens through
pattern-recognition receptors (PRRs), e.g., Toll-like receptors
found on pathogen-associated molecular patterns (PAMPs) (70).
BV anti-inflammatory properties (44) may inhibit the activity
of inflammatory antigens, reduce the number of infiltrated
inflammatory cells, and inhibit the expression of (TNF)-α, IL-
1β, Toll-like receptor (TLR)2 and CD14 expression, suppressing
the binding activity of nuclear factor-κB (NF-κB) and activator
protein (AP)-1 (71). The main Bet V 1 allergen, PLA2, stimulates
the innate immune system, binding to PRRs, e.g., Toll-like
receptors that recognize PAMPs, triggering a type 2 immune
response in mice. PLA2 in BV induces T helper type 2 (Th2)
cell-type reactions and group 2 innate lymphoid cell (ILC2)
activation via the enzymatic cleavage ofmembrane phospholipids
and secretion of IL-33. PLA2 induces the production of IgE,
protecting mice from future allergic/immunologic reactions in
the case of a lethal dose of BV (70); PLA2 plays a critical role in
host defense by improving Th2 differentiation, ILC2 activation,
immunoglobulin production, membrane remodeling, and anti-
inflammatory reactions (44, 70).
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BEE VENOM VACCINES
BV can suppress the progression of tumors and activate the
immune system by combining secretory phospholipase A2
in BV with compounds including phosphatidylinositol-(3,4)-
bisphosphate or dendritic cells (DCs) (66). DCs treated with
BV in vivo show anticancer and antiviral properties. DCs
combined with antigens from a tumor or virus can produce
major histocompatibility complex (MHC) class I and class II
peptide epitopes to CD8 and CD4T lymphocytes, leading to
a series of immune reactions in response to the antigens. BV
phospholipase A2 (bvPLA2-H34Q) is membrane-binding and
links antigens within the cell membrane of human DCs in
vivo. This induces recognition by and activation of CD8T
cells with the implication that antiviral and antitumor vaccines
may be derived from BV (DC vaccine). Vaccines from BV
and DCs (cell-based antiviral/antitumor vaccines) are used
for immunization against viruses such as cytomegalovirus
and for suppression of tumors (73, 74). BV can be used
as a potent adjuvant-potentiated antimicrobial and antitumor
vaccine and shows potential in vaccines where melittin.
sPLA2 and phosphatidylinositol-(3,4)-bisphosphate are effective
adjuvants (anti-leishmania, antitumor and anti-cytomegalovirus
vaccines) (73–75).
A leading adjuvant of SARS-CoV-2 therapies currently
being promoted is aluminum hydroxide due to its slow
release and increased interaction with antigen presenting cells
(115). Bee venom offers a candidate for control SARS-CoV-
2 infections and could offer advantages against COVID-19.
PLA2 has been associated with a level of success against
SARS-CoV-2 infections (116, 117). Conjugation of BV peptides
could offer a new approach in the development of the
BV vaccine.
POTENTIAL RELATIONSHIP BETWEEN
BEE VENOM PROTEINS AND COVID-19
PROTEINS
SARS-CoV-2 belongs to the β-coronavirus genus. SARS-CoV-
2 has four obvious structural proteins: membrane, spike,
nucleocapsid proteins, and envelope. The structural integrity
of the SARS-CoV-2 virus is maintained by structural proteins
and forms a protective coat around its RNA. The coronavirus
membrane contains 3 or 4 viral proteins (118, 119), the
membrane glycoprotein is the most abundant structural protein
and spans the membrane bilayer three times, with a long
COOH terminus inside the virion and a short NH2-terminal
domain outside the virus (120). The SARS-CoV-2 genome
encodes several reading frames (ORFs); ORF1a/b codes for
16 non-structural proteins and translates two polyproteins
(pp1a and pp1ab) accounting for up to 2/3 of the viral
RNA. The remaining ORFs code for structural proteins
(spike glycoprotein, matrix protein, nucleocapsid protein, and
small envelope protein) (118, 119). SARS-CoV-2 has accessory
proteins that interfere with the innate immune response of the
host (118).
The spike protein is usually a Type I membrane glycoprotein
and constitutes the peplomers, known for involvement in
antibody interaction. The membrane plays a significant role in
the intracellular formation of virus particles independent of the
viral spike. Coronaviruses grow and produce spikeless forms in
the presence of tunicamycin, thereby resulting in the production
of non-infectious virions that contain membranes but without
spikes (118).
Melittin can puncture the protective membrane envelopes
surrounding viruses, including human immunodeficiency virus
(HIV) (119). Many viruses, including SARS-CoV-2, rely on their
protective envelope andmay be vulnerable inmelittin-guided bee
venom therapy (Table 1).
The phospholipase A2 components of bee venom have
the potential for antiviral activities (121). Melittin-loaded
nanoparticles delivered a significant amount of melittin
intravenously, targeting and killing precancerous lesions in
K14-HPV16 mice with squamous dysplasia and carcinoma
containing human papillomavirus (HPV) transgenic elements
(E6 and E7 oncogenes) (122, 123).
In Hubei Province, the epicenter of the SARS-CoV-2
outbreak in China, the local beekeeper association surveyed
5,115 beekeepers between 23rd February and 8th March
(including 723 in Wuhan) and showed that none developed
any symptoms observed for COVID-19 patients (124). Five
apitherapists in Wuhan and 121 of their patients who had
received apitherapy between October and December 2019 were
interviewed; two apitherapists were exposed to suspected and/or
confirmed COVID-19 victims without protection. None of
the apitherapists developed symptoms associated with SARS-
CoV-2 and none of their 121 patients contracted COVID
19, despite 3 having been exposed to SARS-CoV-2-infected
relatives (124).
Apitherapy employs honeybees and their products (BV, honey,
royal jelly, pollen, propolis, beeswax). BV therapy uses venom
to modulate the body’s immune system and improve/facilitate
healing and includes either the use of live bee stings or injectable
venom for the management of arthritis, rheumatoid arthritis,
multiple sclerosis (MS), lupus, sciatica, low back pain, and tennis
elbow (125, 126). Hymenopteran products are potent accelerators
of wound healing (127). Insect venoms are less complex and
less variable in composition and physiological activity compared
to snake venoms (125, 126). BV can be administered to induce
allergic immune responses, stimulating the innate immune
system of the host (68), due to the presence of allergens that
promote the type 2 immune responses (44, 68–71). BV antiviral
and antitumor action when BV secretory phospholipase A2 is
mixed with other compounds, such as phosphatidylinositol-
(3,4)-bisphosphate or dendritic cells, and/or bee proteins,
such as melittin, is advantageous (66) and employed in the
production of cell-based antiviral/antitumor vaccines (73–75).
The immunological properties of BV are also found in natural
products that mimic bee venom (127, 128), and further studies
regarding the role of bee venom as a potential candidate for use in
complementary medicine for the management of viruses such as
SARS-CoV-2 could consider other natural products that mimick
BV activity.
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FUTURE RESEARCH ON BEE VENOM
The development of adjuvant therapies (using APi M and
PLA2) to use against SARS-CoV-2 infections offers a unique
approach to viral therapy. Bee venom vaccine development
using DCs using APi M and bvPLA2 offers a new opportunity
for complementary medicine interventions against SARS-
CoV-2 infections. Studies to examine cellular signaling
between BV proteins, Janus Kinase (JAK) and activator of
transcription (JAK-STAT) would help strengthen its adoption
in complementary medicine against SARS-CoV-2. Inhibitors
of JAK are associated with improved prognosis in COVID-19
patients (72, 129) but studies are needed to elucidate the cellular
mechanisms. Synergistic activity through combinations in
alternative and complementary medicine would help combat
side effects associated with current monotherapies for the
management of SARS-CoV-2 infections. SARS-CoV-2 is a
novel virus and novel therapies may be needed to support
management over time and may be of value in supporting
the immune response in patients suffering from so called
long-COVID.
CONCLUSION
SARS-CoV-2 effects on the ACE2 receptors have been associated
with severe inflammatory activity and a poor prognosis,
depending on the co-morbities of the patient and other associated
risk factors. Even if patient recover from initial infection, they
may be faced with a long and complicated convalescence and/
or so called, long-COVID. It is unlikey that there will be a magic
bullet therapy for COVID-19 soon, and complimentary therapies
should be explored that compliment conventional therapy
and support healthy recovery. BV melittin and phospholipase
A2 activity have strong anti-inflammatory action and could
be deployed to support recovery. That BV has successfully
been used to manage neurological and immunological diseases
strengthens the case for exploration of its use in complimentary
medicine for SARS-CoV-2 infections. BV is a potential adjuvant
against COVID-19 which should be added to the list of
major therapies.
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